2024-03-05 |
2024-03-04 |
V
Vente
|
Kenkare-Mitra Sara
President and Head of R&D
Dirigeant
|
10 169
-3.1%
6,92
70 387
USD
|
10 169
-3.1%
|
6,92
|
70 387
USD
|
|
2024-03-05 |
2024-03-04 |
V
Vente
|
GRASSO MARC
Chief Financial Officer
Dirigeant
|
5 716
-3.8%
6,92
39 562
USD
|
5 716
-3.8%
|
6,92
|
39 562
USD
|
|
2024-03-05 |
2024-03-04 |
V
Vente
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
18 837
-0.9%
6,92
130 386
USD
|
18 837
-0.9%
|
6,92
|
130 386
USD
|
|
2024-03-05 |
2024-03-04 |
V
Vente
|
Romano Gary
Chief Medical Officer
Dirigeant
|
6 001
-3.0%
6,92
41 554
USD
|
6 001
-3.0%
|
6,92
|
41 554
USD
|
|
2023-12-06 |
2023-12-04 |
V
Vente
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
23 831
-1.2%
5,56
132 500
USD
|
23 831
-1.2%
|
5,56
|
132 500
USD
|
|
2023-12-06 |
2023-12-04 |
V
Vente
|
GRASSO MARC
Chief Financial Officer
Dirigeant
|
4 574
-2.9%
5,56
25 431
USD
|
4 574
-2.9%
|
5,56
|
25 431
USD
|
|
2023-12-06 |
2023-12-04 |
V
Vente
|
Kenkare-Mitra Sara
President and Head of R&D
Dirigeant
|
12 519
-3.7%
5,56
69 606
USD
|
12 519
-3.7%
|
5,56
|
69 606
USD
|
|
2023-12-06 |
2023-12-04 |
V
Vente
|
Romano Gary
Chief Medical Officer
Dirigeant
|
5 035
-2.4%
5,56
27 995
USD
|
5 035
-2.4%
|
5,56
|
27 995
USD
|
|
2023-09-13 |
2023-09-11 |
V
Vente
|
Polaris Venture Management Co. VI, L.L.C.
Actionnaire important
|
500 000
-4.4%
6,00
3 000 000
USD
|
500 000
-4.4%
|
6,00
|
3 000 000
USD
|
|
2023-09-13 |
2023-09-11 |
V
Vente
|
MCGUIRE TERRANCE
Administrateur non-exécutif
Actionnaire important
|
500 000
-4.4%
6,00
3 000 000
USD
|
500 000
-4.4%
|
6,00
|
3 000 000
USD
|
|
2023-09-06 |
2023-09-05 |
V
Vente
|
Romano Gary
Chief Medical Officer
Dirigeant
|
2 771
-2.7%
5,19
14 393
USD
|
2 771
-2.7%
|
5,19
|
14 393
USD
|
|
2023-09-06 |
2023-09-05 |
V
Vente
|
Kenkare-Mitra Sara
President and Head of R&D
Dirigeant
|
6 214
-3.4%
5,19
32 277
USD
|
6 214
-3.4%
|
5,19
|
32 277
USD
|
|
2023-09-06 |
2023-09-05 |
V
Vente
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
5 647
-0.3%
5,19
29 333
USD
|
5 647
-0.3%
|
5,19
|
29 333
USD
|
|
2023-09-06 |
2023-09-05 |
V
Vente
|
GRASSO MARC
Chief Financial Officer
Dirigeant
|
1 114
-3.3%
5,19
5 786
USD
|
1 114
-3.3%
|
5,19
|
5 786
USD
|
|
2023-06-05 |
2023-06-02 |
V
Vente
|
GRASSO MARC
Chief Financial Officer
Dirigeant
|
1 050
-3.1%
6,90
7 249
USD
|
1 050
-3.1%
|
6,90
|
7 249
USD
|
|
2023-06-05 |
2023-06-02 |
V
Vente
|
Romano Gary
Chief Medical Officer
Dirigeant
|
2 617
-2.5%
6,90
18 067
USD
|
2 617
-2.5%
|
6,90
|
18 067
USD
|
|
2023-06-05 |
2023-06-02 |
V
Vente
|
Kenkare-Mitra Sara
President and Head of R&D
Dirigeant
|
4 092
-2.2%
6,90
28 250
USD
|
4 092
-2.2%
|
6,90
|
28 250
USD
|
|
2023-06-05 |
2023-06-02 |
V
Vente
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
5 255
-0.3%
6,90
36 279
USD
|
5 255
-0.3%
|
6,90
|
36 279
USD
|
|
2023-03-21 |
2023-03-17 |
V
Vente
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
15 186
-0.9%
6,22
94 428
USD
|
15 186
-0.9%
|
6,22
|
94 428
USD
|
|
2023-03-03 |
2023-03-02 |
V
Vente
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
5 849
-0.4%
8,32
48 651
USD
|
5 849
-0.4%
|
8,32
|
48 651
USD
|
|
2023-03-03 |
2023-03-02 |
V
Vente
|
Romano Gary
Chief Medical Officer
Dirigeant
|
3 238
-3.0%
8,32
26 933
USD
|
3 238
-3.0%
|
8,32
|
26 933
USD
|
|
2023-03-03 |
2023-03-02 |
V
Vente
|
GRASSO MARC
Chief Financial Officer
Dirigeant
|
1 291
-3.6%
8,32
10 739
USD
|
1 291
-3.6%
|
8,32
|
10 739
USD
|
|
2023-03-03 |
2023-03-02 |
V
Vente
|
Kenkare-Mitra Sara
President and Head of R&D
Dirigeant
|
10 124
-5.1%
8,32
84 216
USD
|
10 124
-5.1%
|
8,32
|
84 216
USD
|
|
2023-03-03 |
2022-12-02 |
V
Vente
|
Romano Gary
Chief Medical Officer
Dirigeant
|
2 145
-1.9%
8,71
18 679
USD
|
2 145
-1.9%
|
8,71
|
18 679
USD
|
|
2022-09-07 |
2022-09-02 |
V
Vente
|
King Robert
Chief Development Officer
Dirigeant
|
176
-0.0%
10,62
1 869
USD
|
176
-0.0%
|
10,62
|
1 869
USD
|
|
2022-09-07 |
2022-09-02 |
V
Vente
|
Romano Gary
Chief Medical Officer
Dirigeant
|
2 177
-2.4%
10,62
23 120
USD
|
2 177
-2.4%
|
10,62
|
23 120
USD
|
|
2022-06-06 |
2022-06-02 |
VP
Vente planifiée
|
King Robert
Chief Development Officer
Dirigeant
|
177
-0.0%
8,71
1 542
USD
|
177
-0.0%
|
8,71
|
1 542
USD
|
|
2022-03-03 |
2022-03-01 |
V
Vente
|
King Robert
Chief Development Officer
Dirigeant
|
287
-0.1%
15,57
4 468
USD
|
287
-0.1%
|
15,57
|
4 468
USD
|
|
2021-12-14 |
2021-12-13 |
VP
Vente planifiée
|
SULIMAN SHEHNAAZ
President and COO
Dirigeant
|
10 898
-9.6%
21,73
236 802
USD
|
10 898
-9.6%
|
21,73
|
236 802
USD
|
|
2021-12-14 |
2021-12-13 |
VP
Vente planifiée
|
SULIMAN SHEHNAAZ
President and COO
Dirigeant
|
64 102
-36.1%
21,16
1 356 347
USD
|
64 102
-36.1%
|
21,16
|
1 356 347
USD
|
|
2021-12-14 |
2021-12-10 |
VP
Vente planifiée
|
SULIMAN SHEHNAAZ
President and COO
Dirigeant
|
8 874
-8.0%
22,33
198 192
USD
|
8 874
-8.0%
|
22,33
|
198 192
USD
|
|
2021-12-14 |
2021-12-10 |
VP
Vente planifiée
|
SULIMAN SHEHNAAZ
President and COO
Dirigeant
|
66 126
-37.2%
21,69
1 433 975
USD
|
66 126
-37.2%
|
21,69
|
1 433 975
USD
|
|
2021-12-10 |
2021-12-09 |
VP
Vente planifiée
|
SULIMAN SHEHNAAZ
President and COO
Dirigeant
|
2 643
-2.5%
23,40
61 858
USD
|
2 643
-2.5%
|
23,40
|
61 858
USD
|
|
2021-12-10 |
2021-12-09 |
VP
Vente planifiée
|
SULIMAN SHEHNAAZ
President and COO
Dirigeant
|
72 357
-40.7%
22,80
1 649 986
USD
|
72 357
-40.7%
|
22,80
|
1 649 986
USD
|
|
2021-12-10 |
2021-12-08 |
VP
Vente planifiée
|
SULIMAN SHEHNAAZ
President and COO
Dirigeant
|
38 489
-27.3%
23,01
885 690
USD
|
38 489
-27.3%
|
23,01
|
885 690
USD
|
|
2021-12-10 |
2021-12-08 |
VP
Vente planifiée
|
SULIMAN SHEHNAAZ
President and COO
Dirigeant
|
36 511
-20.6%
22,56
823 626
USD
|
36 511
-20.6%
|
22,56
|
823 626
USD
|
|
2021-12-03 |
2021-12-01 |
VP
Vente planifiée
|
King Robert
Chief Development Officer
Dirigeant
|
250
-0.0%
20,09
5 023
USD
|
250
-0.0%
|
20,09
|
5 023
USD
|
|
2021-11-12 |
2021-11-11 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
55 000
-2.7%
25,00
1 375 000
USD
|
55 000
-2.7%
|
25,00
|
1 375 000
USD
|
|
2021-11-12 |
2021-11-10 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
55 000
-2.6%
25,00
1 375 000
USD
|
55 000
-2.6%
|
25,00
|
1 375 000
USD
|
|
2021-11-10 |
2021-11-09 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
15 000
-2.2%
25,00
375 000
USD
|
15 000
-2.2%
|
25,00
|
375 000
USD
|
|
2021-11-10 |
2021-11-09 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
15 000
-2.2%
25,00
375 000
USD
|
15 000
-2.2%
|
25,00
|
375 000
USD
|
|
2021-11-10 |
2021-11-09 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
15 000
-2.2%
25,00
375 000
USD
|
15 000
-2.2%
|
25,00
|
375 000
USD
|
|
2021-11-10 |
2021-11-09 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
55 000
-2.6%
25,00
1 375 000
USD
|
55 000
-2.6%
|
25,00
|
1 375 000
USD
|
|
2021-11-10 |
2021-11-08 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
15 000
-2.2%
25,00
375 000
USD
|
15 000
-2.2%
|
25,00
|
375 000
USD
|
|
2021-11-10 |
2021-11-08 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
15 000
-2.2%
25,00
375 000
USD
|
15 000
-2.2%
|
25,00
|
375 000
USD
|
|
2021-11-10 |
2021-11-08 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
15 000
-2.2%
25,00
375 000
USD
|
15 000
-2.2%
|
25,00
|
375 000
USD
|
|
2021-11-10 |
2021-11-08 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
55 000
-2.5%
25,00
1 375 000
USD
|
55 000
-2.5%
|
25,00
|
1 375 000
USD
|
|
2021-11-08 |
2021-11-05 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
15 000
-2.2%
25,00
375 000
USD
|
15 000
-2.2%
|
25,00
|
375 000
USD
|
|
2021-11-08 |
2021-11-05 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
15 000
-2.2%
25,00
375 000
USD
|
15 000
-2.2%
|
25,00
|
375 000
USD
|
|
2021-11-08 |
2021-11-05 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
15 000
-2.2%
25,00
375 000
USD
|
15 000
-2.2%
|
25,00
|
375 000
USD
|
|
2021-11-08 |
2021-11-05 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
55 000
-2.4%
25,00
1 375 000
USD
|
55 000
-2.4%
|
25,00
|
1 375 000
USD
|
|
2021-11-08 |
2021-11-04 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
15 000
-2.1%
25,00
375 000
USD
|
15 000
-2.1%
|
25,00
|
375 000
USD
|
|
2021-11-08 |
2021-11-04 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
15 000
-2.1%
25,00
375 000
USD
|
15 000
-2.1%
|
25,00
|
375 000
USD
|
|
2021-11-08 |
2021-11-04 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
15 000
-2.1%
25,00
375 000
USD
|
15 000
-2.1%
|
25,00
|
375 000
USD
|
|
2021-11-08 |
2021-11-04 |
VP
Vente planifiée
|
Rosenthal Arnon
Chief Executive Officer
Administrateur exécutif
|
55 000
-2.4%
25,00
1 375 000
USD
|
55 000
-2.4%
|
25,00
|
1 375 000
USD
|
|
2021-07-08 |
2021-07-07 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
17 149
-6.8%
39,32
674 220
USD
|
17 149
-6.8%
|
39,32
|
674 220
USD
|
|
2021-07-08 |
2021-07-07 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
7 700
-3.0%
38,14
293 686
USD
|
7 700
-3.0%
|
38,14
|
293 686
USD
|
|
2021-07-08 |
2021-07-07 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
4 900
-1.9%
37,41
183 332
USD
|
4 900
-1.9%
|
37,41
|
183 332
USD
|
|
2021-07-08 |
2021-07-06 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
1 100
-0.5%
40,01
44 016
USD
|
1 100
-0.5%
|
40,01
|
44 016
USD
|
|
2021-07-08 |
2021-07-06 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
10 495
-4.3%
39,20
411 411
USD
|
10 495
-4.3%
|
39,20
|
411 411
USD
|
|
2021-07-08 |
2021-07-06 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
3 581
-1.4%
38,55
138 059
USD
|
3 581
-1.4%
|
38,55
|
138 059
USD
|
|
2021-07-08 |
2021-07-06 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
1 000
-0.4%
37,43
37 434
USD
|
1 000
-0.4%
|
37,43
|
37 434
USD
|
|
2021-07-08 |
2021-07-06 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
3 600
-1.4%
35,95
129 433
USD
|
3 600
-1.4%
|
35,95
|
129 433
USD
|
|
2021-07-08 |
2021-07-06 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
10 224
-3.9%
35,10
358 813
USD
|
10 224
-3.9%
|
35,10
|
358 813
USD
|
|
2021-06-21 |
2021-06-16 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
4 600
-1.7%
22,18
102 049
USD
|
4 600
-1.7%
|
22,18
|
102 049
USD
|
|
2021-06-21 |
2021-06-15 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
30 000
-9.9%
22,07
661 953
USD
|
30 000
-9.9%
|
22,07
|
661 953
USD
|
|
2021-06-10 |
2021-06-08 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
800
-0.3%
20,83
16 661
USD
|
800
-0.3%
|
20,83
|
16 661
USD
|
|
2021-06-10 |
2021-06-08 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
2 200
-0.8%
19,89
43 753
USD
|
2 200
-0.8%
|
19,89
|
43 753
USD
|
|
2021-06-10 |
2021-06-08 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
16 175
-5.5%
19,00
307 331
USD
|
16 175
-5.5%
|
19,00
|
307 331
USD
|
|
2021-05-25 |
2021-05-21 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
14 975
-5.2%
18,14
271 681
USD
|
14 975
-5.2%
|
18,14
|
271 681
USD
|
|
2021-05-20 |
2021-05-18 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
4 200
-1.5%
18,04
75 786
USD
|
4 200
-1.5%
|
18,04
|
75 786
USD
|
|
2021-04-08 |
2021-04-07 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
45
-0.0%
19,83
892
USD
|
45
-0.0%
|
19,83
|
892
USD
|
|
2021-04-08 |
2021-04-07 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
22 255
-9.4%
19,19
427 158
USD
|
22 255
-9.4%
|
19,19
|
427 158
USD
|
|
2021-03-24 |
2021-03-23 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
13 800
-6.1%
22,21
306 498
USD
|
13 800
-6.1%
|
22,21
|
306 498
USD
|
|
2021-03-24 |
2021-03-22 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
5 510
-2.5%
23,55
129 774
USD
|
5 510
-2.5%
|
23,55
|
129 774
USD
|
|